Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target

Benzinga Newsdesk www.benzinga.com Negative 75.5%

Neg 75.5% Neu 0% Pos 0%

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $55 price target.